20-02-39 Genetic Testing and Screening: Putting it All Together - Who to Test, What to Test and When to Test

23rd Annual Premier Women's Healthcare Virtual Conference

3.5 CE (NCC 3)

Individuals who did not register for the Conference can now purchase individual session recordings. Anyone who was registered for the Main Conference (October 16-17, 2020) will have access to all recordings, free of any additional charge, through November 15, 2021.



Haywood Brown MD,

Associate Dean, USF Health VP Office

VP, Diversity and Associate Dean MCOM

University of South Florida

Tampa, FL

Rachel Gorham-Fidino MSN, WHNP, AGN-BC

New Women’s Clinic and Aesthetics

Kennewick, WA

Holly Pederson MD, NCMP

Director, Medical Breast Services

Cleveland Clinic

Cleveland, OH

 Intended Audience:

Women’s Health Nurse Practitioners (WHNPs), WHNP students, Certified Nurse Midwives (CNMs) and other nurse practitioners and advanced practice clinicians who care for women.

 Activity Number:  20-02-39

 CE Approval Period:  Now through November 15, 2021

 Approved CE Credit Hours:  3.5 CE contact hour credits, zero hours pharmacology credit

 Accreditation Statement:

This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health for 3.5 CE contact hours, zero hours of pharmacology content. 

 Program Description

This workshop will provide a general overview of the role of the nurse practitioner regarding risk assessment, screening, and testing, and when to refer. The field of genetic testing and screening has expanded in recent years. As we learn more about the role our genetic make-up plays in many disease processes it is important to know and provide our patients with updated, evidence-based information.

 Educational Objectives:

At the conclusion of this activity, the learner will be able to:

1.Capture a family history to identify appropriate genetic screening and testing.  

2. Appreciate advantages of NGS for carrier detection status for a large variety of genes implicated in inheritable genetic disorders in a multiethnic society 

3. Counsel patients on hereditary cancer syndromes and relevance to clinical practice.

 Faculty Disclosures:

Haywood Brown, MD has the following disclosure:  Medical Director, Access to Expanded Carrier Screening (AESC)

Rachel Gorham Fidino has no reported disclosures

Holly Pederson MD, NCMP has no reported disclosures

 Successful Completion:

Successful completion of this activity requires the participant to:

  1. Read the educational objectives, disclosures, and disclaimers.
  2. Watch the session recording
  3. Complete the session evaluation
  4. Print your CE certificate (the certificate will be stored on the NPWH E-Learning site under My Transcripts).
  5. These steps must be completed prior to the course expiration date
  6. Some courses required a post-test.  If a post test is required participants must earn a score of 70%.   

Therapeutic Disclosures:

Faculty members determine the content of the CE activity.  The content does not necessarily represent the views of NPWH.  Clinicians are responsible for evaluating information presented in relation to generally accepted standards of care and individual patient characteristics.

 Commercial Support: 

This activity has no commercial support

 You must be signed in to access this course.  You can sign in at the top right-hand corner of the page.

 **If you are an NPWH member, were once a member, or have completed CE activities with NPWH in the past, you have a username and password in the system.  Please DO NOT create a new account.  If you do not remember your username or password, please either click on the “forgot username” or “forgot password” link at the bottom of the sign on screen or call the NPWH office at (202) 543-9693 ext. 81


Non-Member/Inactive Member Student Member
$120.00 $60.00 $60.00
20-02-39 Genetic Testing and Screening:  Putting it All Together - Who to Test, What to Test and When to Test